NSE: PGHL | BSE: 500126

Mid-range Performer

Download real time

5670.00 30.00 (0.53%)

2,768 NSE+BSE Volume

NSE 23 Dec, 2025 3:31 PM (IST)

9,411.9

Market Cap

High in industry

Beta 1Year

Very Low volatility

Procter & Gamble Health Ltd. share price target and research reports

Name: Latest research reports of Procter & Gamble Health Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Procter & Gamble Health Ltd.
Rating: 5
Author: ICICI Direct

Latest analyst research reports with target prices and PDF download for PGHL, BSE:500126 Procter & Gamble Health Ltd.

Search Inside the pdf :

Procter & Gamble Health Ltd.

16 May 2023

5670.00

0.53%

P&G Health

Buy: Procter & Gamble Health Ltd.

Target

ICICI Direct

Number of FII/FPI investors increased from 149 to 160 in Sep 2025 qtr.

Procter & Gamble Health Ltd.

06 Feb 2023

5670.00

0.53%

P&G Health

Buy: Procter & Gamble Health Ltd.

Recommendation Target

ICICI Direct

Number of FII/FPI investors increased from 149 to 160 in Sep 2025 qtr.

Procter & Gamble Health Ltd.

30 Aug 2022

5670.00

0.53%

P&G Health

Hold: Procter & Gamble Health Ltd.

Target

ICICI Direct

Procter & Gamble Health Ltd. is trading below all available SMAs

Procter & Gamble Health Ltd.

06 May 2022

5670.00

0.53%

P&G Health

Hold: Procter & Gamble Health Ltd.

ICICI Direct

Number of FII/FPI investors increased from 149 to 160 in Sep 2025 qtr.

Procter & Gamble Health Ltd.

27 Aug 2021

5670.00

0.53%

P&G; Health

Buy: Procter & Gamble Health Ltd.

Target

ICICI Securities Limited

What should investors do? PGHL share price has grown by ~7.5x over the past five years (from ~| 728 in Aug 2016 to ~| 5530 levels in Aug 2021). We change our rating from HOLD to BUY rating on the stock given the good...

Number of FII/FPI investors increased from 149 to 160 in Sep 2025 qtr.

Procter & Gamble Health Ltd.

17 Sep 2020

5670.00

0.53%

P&G; Health

Buy: Procter & Gamble Health Ltd.

Target

ICICI Securities Limited

PGHL is a pharma cum consumer OTC player with strong and legacy brands in the vitamin minerals & supplement (VMS) category like Neurobion, Polybion, Evion (all vitamins), Livogen (iron supplement), Nasivion (nasal decongestant), Seven Seas (vitamin- substitute for malt based health drinks). Post the change in ownership (from Merck to P&G;), we expect these known brands to leverage on P&G;'s distribution might as most of these brands are driven by self-medication habit rather than doctor's prescription. It also has a presence in the prescription based cardio-diabetology category....

Procter & Gamble Health Ltd. is trading below all available SMAs

Procter & Gamble Health Ltd.

10 Aug 2018

5670.00

0.53%

Result Review of Merck

Sell: Procter & Gamble Health Ltd.

Recommendation Target

IDBI Capital

Merck's Q2CY18 results were a mix bag. Topline was 27.2% below our estimates given the divestment in the business, however PAT was 7.6% above our estimates given better than expected EBITDA. Sales grew by 33.3% YoY to Rs2.2bn. EBITDA margins were at 23.1% up QoQ from 12% given higher gross margins and reduced OE. APAT was...

Number of FII/FPI investors increased from 149 to 160 in Sep 2025 qtr.

Procter & Gamble Health Ltd.

02 May 2018

5670.00

0.53%

Result Review of Merck

Accumulate: Procter & Gamble Health Ltd.

IDBI Capital

due to substantial increase in other expenses. Adj. PAT of Rs162mn was up 9.4% at Mumbai which was held for sale resulted in Extraordinary Loss. We have not revised our CY18E/CY19E numbers. We initiated on this stock at a CMP of Rs1,010, after reaching our TP, we revise our...

Procter & Gamble Health Ltd. is trading below all available SMAs

Procter & Gamble Health Ltd.

26 Feb 2018

5670.00

0.53%

Result Review of Merck

Accumulate: Procter & Gamble Health Ltd.

Target

IDBI Capital

Given the change in the product mix, we have maintained our CY18 revenue As we roll one-year forward our valuation to CY19E, taking in account that major products coming out of the purview NLEM and continuous launches in the Indian...

Number of FII/FPI investors increased from 149 to 160 in Sep 2025 qtr.

Procter & Gamble Health Ltd.

26 Feb 2018

5670.00

0.53%

Merck

Hold: Procter & Gamble Health Ltd.

Target

Centrum Broking

Chemical segment revenue grew 27%YoY: Merck's pharma segment's revenue grew 14%YoY to Rs2.24bn from Rs1.96bn due to re-stocking by trade post successful GST implementation. Merck is a pioneer in the vitamin segment, with three major brands Neurobion, Polybion and Evion. Evion does not fall under the National List of Essential Medicines (NLEM) and hence its price hasn't been capped. The company's chemical business (26% of revenues) grew by 27%YoY. We expect the high-margin pharma business to drive future growth. Margin grew by 340bps YoY: Merck's EBIDTA margin grew by 340bps YoY to 15.8%...

Number of FII/FPI investors increased from 149 to 160 in Sep 2025 qtr.

Is Procter & Gamble Health Ltd. worth buying?

224 Votes:

Buy 72.77%

Sell 17.86%

Hold 9.38%